Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on harnessing the human microbiome to develop novel therapeutics. The company specializes in microbiome-based live biological therapies designed to restore health in patients suffering from a range of gastrointestinal, metabolic and immune-mediated disorders. Through its proprietary Microbiome+™ platform, Finch Therapeutics identifies and refines microbial consortia derived from healthy donor samples to address diseases associated with microbial dysbiosis.
Finch’s lead product candidate, CP101, is being evaluated for the prevention of recurrent Clostridioides difficile infection (rCDI), and the company has reported promising data from Phase 2 clinical trials. In addition to CP101, Finch is advancing FT-5A and FT-5B, oral formulations targeting inflammatory bowel disease, and several earlier-stage programs aimed at central nervous system and oncology indications. Finch collaborates with academic institutions, contract research organizations and strategic partners to conduct multi-center clinical studies across North America and Europe.
Founded in 2015 and headquartered in Somerville, Massachusetts, Finch Therapeutics has established manufacturing capabilities for live biotherapeutics in the United States. The company’s research and development activities are complemented by a network of clinical sites and partnerships that extend its reach into international markets. Finch has secured funding through public offerings and strategic alliances, underscoring investor confidence in its microbiome-based approach.
Finch Therapeutics is led by Mark Smith, who serves as President and Chief Executive Officer, bringing more than two decades of experience in biotechnology and pharmaceutical development. The executive team includes experts in microbial ecology, clinical development, regulatory affairs and commercial strategy. Under this leadership, Finch continues to build a pipeline of next-generation microbiome therapies with the goal of transforming patient care in areas of high unmet medical need.
AI Generated. May Contain Errors.
